Clinical trials: Gastric Cancer, completed
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment.
- Conditions
- Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma
- Trial name
- NCT00633789
- Testing
- brivanib
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 597 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Enterotomy Closure and Minimally Invasive Gastrectomy
All consecutive patients from January 2009 to december 2019 who underwent minimally invasive partial gastrectomy for gastric cancer at thirteen high volume institutions will be retrospective analysed to assess the better way to…
- Trial name
- NCT04901585
- Testing
- Totally intracorporeal distal gastrectomy
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Federico II University
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Gastric Cancer
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have unresectable or…
- Trial name
- NCT00074009
- Testing
- bortezomib
- Where
- 4 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Gastric Cancer
S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182611
- Testing
- cisplatin, tegafur-gimeracil-oteracil potassium, adjuvant therapy
- Where
- 6 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
Renal Cell Carcinoma Metastatic, Breast Cancer
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home.
- Conditions
- Renal Cell Carcinoma Metastatic, Breast Cancer, Head and Neck Cancer, Thyroid Cancer
- Trial name
- CAPABLE-IT (NCT06161233)
- Testing
- CAPABLE cohort
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Gastroenteropancreatic Neuroendocrine Tumors
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
This study is for patients with non-resectable, recurrent, or metastatic well or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Trial name
- PLANET (NCT03043664)
- Testing
- Lanreotide, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Duke University
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Gastro-intestinal Stromal Tumours
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
- Trial name
- NCT00998751
- Testing
- oral masitinib
- Where
- France
- Volunteers
- 30 people
- Sponsor
- AB Science
Gastric Cancer
Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer…
- Trial name
- NCT00595972
- Testing
- ECF-endostar
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Marginal Zone Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
- Trial name
- NCT00453102
- Testing
- Rituximab, Ibritumomab Tiuxetan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Miami
Gastric Cancer
The Diagnostic Value of Staging Laparoscopy and Computed Tomography Response Assessment in Patients With Gastric Adenocarcinoma
SUMMARY Rationale: Diagnostic laparoscopy (DL) and response assessment after neoadjuvant chemotherapy with computed tomography (CT) are two diagnostic modalities used to assess metastatic spread in gastric cancer patients.
- Trial name
- NCT05013775
- Testing
- Computed tomography, Diagnostic laparoscopy with peritoneal lavage
- Where
- Netherlands
- Volunteers
- 697 people
- Sponsor
- Sander van Hootegem
Lynch Syndrome, FAP
Hereditary Colorectal and Associated Tumor Registry Study
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample.
- Conditions
- Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome
- Trial name
- NCT00633607
- Testing
- Research Registry
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Pittsburgh
Gastric Cancer, Gastric Adenocarcinoma
Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after curative tumor resection subsequent to a neoadjuvant…
- Trial name
- NCT00464893
- Testing
- Catumaxomab
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 70 people
- Sponsor
- Neovii Biotech
Gastric Cancer
A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer
Gastric cancer is the most common malignancy in Korea. The prognosis of unresectable gastric cancer has been improved by cytotoxic chemotherapy, but median survival rarely exceeds 1 year.
- Trial name
- DO for AGC (NCT00533533)
- Testing
- docetaxel, oxaliplatin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Samsung Medical Center
Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
This early phase I trial studies how well pembrolizumab works in treating patients with gastroesophageal adenocarcinoma that has spread to other places or cannot be removed by surgery.
- Conditions
- Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT03395847
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study
In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or…
- Trial name
- NCT03978481
- Testing
- Helicobacter pylori eradication (combination therapy)
- Where
- South Korea
- Volunteers
- 3,700 people
- Sponsor
- Seoul National University Bundang Hospital
Gastric Cancer
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic…
- Trial name
- NCT06573307
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Chang-Ming Huang, Prof.
Gastric Cancer
Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Gastric cancer (GC) is a leading global health problem and is the third most common cause of cancer related death. Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the mainstay treatment for locally advanced gastric…
- Trial name
- MENCA-GC (NCT03425058)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.